Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review-Reference-Cited by-同舟云学术

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review

Published:2018-09-18 Issue:2 Volume:7 Page:293-305
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Fusi-Rubiano William,Blow Rebecca R.,Lane Mark,Morjaria Rupal,Denniston Alastair K.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s40123-018-0145-7.pdf

Reference49 articles.

1. World Health Organization (WHO). Global Report on Diabetes. 2016. http://www.who.int/diabetes/global-report/en/ Accessed 28 May 2018.

2. Diabetes UK. Diabetes Prevalence 2017. https://www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2017 Accessed 3 May 2018.

3. Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98–104.

4. Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond). 2015;29(9):1115.

5. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2–3):309–15.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When;Journal of Clinical Medicine;2024-02-26

2. Current Insights into Targeting Strategies for the Effective Therapy of Diseases of the Posterior Eye Segment;Critical Reviews™ in Therapeutic Drug Carrier Systems;2024

3. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study;International Ophthalmology;2023-09-12

4. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery;Journal of Controlled Release;2023-09

5. Trends in Ophthalmological Patents, 2005–2020;Journal of Ocular Pharmacology and Therapeutics;2023-07-01